P471 CLINICAL AND THERAPEUTIC CHARACTERISTICS OF PATIENTS WITH HEART FAILURE IN THERAPY WITH SGLT2I RELATED TO THE HEART FAILURE OUTPATIENT

Abstract

Abstract Sodium–glucose co–transporter type 2 inhibitors are the new class of drugs that have been shown to reduce heart failure hospitalizations and cardiovascular deaths in patients with HFrEF with a class of recommendation IB for the treatment of patients with HFrEF in the most recent international guidelines. The objective of this observational study was to analyze the main clinical characteristics, therapeutic associations and any adverse events highlighted in outpatients in which SGLT2i therapy was added. Data from 42 patients on SGLT2i therapy (98.2% dapagliflozin) were analysed. 71% of patients were male, with a mean age of 70.5 years. Approximately 52% of cases had an ischemic heart failure aetiology, 54% had arterial hypertension, and 27% had type 2 diabetes mellitus. Of these, 76% had HFrEF, 14% had HFmrEF and the remaining 9% from HFpEF. At the time of the visit, 11.9% of patients had a serum creatinine value > 1.3 mg/dL. Thirty–one percent of patients were NYHA Class III. The analysis of concomitant drug therapies with the use of SGLT2i showed that 76% of patients were on therapy with a renin angiotensin system inhibitor (62% ACEI/ARBs and 14% ARNI), 71% were on MRA and 91% % beta blockers. 82% of patients were on concomitant diuretic therapy with furosemide. ARNI therapy was suspended due to hypotension in 5% of cases (2 patients). No patient had significant renal deterioration requiring discontinuation of SGLT2i. Conclusions From the observed data emerged that the addition of SGLT2i to the optimized therapy is safe and well tolerated. None of the patients had to discontinue this drug and there were no adverse events. The association between SGLT2i and ARNI was also well tolerated and, in accordance with the documented efficacy in the main clinical trials, should be privileged as soon as possible.